The results

The AMBAR trial has demonstrated a significant reduction in the progression of Alzheimer's in moderate patients.

AMBAR, an innovative treatment approach for Alzheimer's disease (AD) based on the combination of Plasmapheresis with Albutein® 20% replacement under development in phase IIb/III, may offer a new treatment pathway for the illness in the future.

Press release

Grifols AMBAR results demonstrate a significant reduction in the progression of moderate Alzheimer's Disease


(+34) 935 710 002

media@grifols.com

"Grifols will continue to explore the potential of plasma proteins and plasma exchange in further studies."

Víctor Grífols, Grifols Chairman

"The results are positive and highly relevant in a cohort of patients suffering from moderate Alzheimer disease."

Antonio Páez, M.D., Grifols Medical Director and Head of the AMBAR Clinical Program

"This is the most significant development in the treatment of patients with moderate Alzheimer's disease I've seen in over 15 years."

Mercè Boada, M.D., Ph.D., Director of Fundació ACE.

"Those findings open new avenues for the research of neurodegenerative disorders that have the potential to offer a new modality of treatment."

Dr. Óscar López, Director of the AD Research Center of the University of Pittsburgh

AMBAR in the media:

 

Date Media Headline
18 NOV, 2018 Infobae Alzheimer: ¿un freno al avance?
13 NOV, 2018 El País Grifols busca la piedra filosofal para curar el alzhéimer
4 NOV, 2018 The Pharma Letter Look back at pharma news in week to November 2 
03 NOV, 2018 El País Prudencia ante el anuncio de una "nueva era" en el tratamiento del alzhéimer
30 OCT, 2018 BioCentury Grifols' AMBAR approach slows disease progression in moderate Alzheimer's
30 OCT, 2018 El Mundo Una técnica española para "limpiar" las proteínas del Alzheimer del cerebro
29 OCT, 2018 ARA "És un dels avenços més importants dels últims 15 anys"
29 OCT, 2018 Correo Farmacéutico Resultados positivos de la terapia de recambio plasmático para Alzheimer
29 OCT, 2018 Diario Médico Resultados positivos de la terapia de recambio plasmático para Alzheimer
29 OCT, 2018 Infobae De qué se trata el ensayo clínico que abre una nueva esperanza para frenar la evolución del Alzheimer
29 OCT, 2018 Labiotech Plasma Replacement Therapy Promising in Alzheimer's Patients
29 OCT, 2018 Reuters BRIEF-Grifols Says AMBAR Results Show Reduction In Progression of Moderate Alzheimer's Disease
29 OCT, 2018 Scrip Pharma Intelligence Grifols Slows Alzheimer's Progression With Plasmapheresis
29 OCT, 2018 The Corner Grifols Offers Hope Of A Treatment For Alzheimer
29 OCT, 2018 The Pharma Letter Grifols' AMBAR protocol shows encouraging results in Alzheimer's 
29 OCT, 2018 Vantage Something seems to work in Alzheimer's – and it's more blood than brain
29 OCT, 2018 WikiTribune Barcelona lab finds treatment that slows down Alzheimer's
28 OCT, 2018 Cinco Días El laboratorio Grifols encuentra una fórmula para ralentizar el progreso del alzhéimer
28 OCT, 2018 La Vanguardia Grifols anuncia su primer hito contra el alzheimer
28 OCT, 2018 RTTNews ESPR To Submit NDAs In Q1, GRFS' Alzheimer's Study Brings Hope, RTRX On Watch
27 OCT, 2018 El País Un fármaco experimental logra ralentizar el alzhéimer
27 OCT, 2018 Expansión Grifols cree que su terapia para el alzhéimer "podría tener una aplicación inmediata"
28 SET, 2017 Nature Therapeutic plasma proteins: their incredible potential as a source of health

 

Alzheimer's Disease

It is currently estimated that 35 million people worldwide suffer from Alzheimer's, and this figure is continuing to grow.

Read more

Grifols and Alzheimer's

Since 2004, we have led a broad range of research initiatives on Alzheimer's.

Read more

The AMBAR hypothesis

AMBAR is an innovative treatment proposal aimed at slowing the progression of Alzheimer's disease through periodic plasma exchange.

Read more

The AMBAR
study

AMBAR is an international and multicenter clinical trial designed by Grifols in collaboration with Fundació ACE in Barcelona, Spain; and the Alzheimer Disease Research Center in Pittsburgh, PA, U.S.

Read more